BASi (Bioanalytical Systems, Inc.) has added the ability to work with large animals through its Culex Automated In Vivo Discovery Services. According to the company, the process offers extensive, faster and more meaningful results to help develop new drugs, while easing the stress on animals. Additionally, the company has added non-clinical scientist Brad Gien to its Culex services team.

The Culex Automated In Vivo Sampling Services offer investigators a way to increase the amount and type of data gathered in drug discovery experiments with small and now large animal models. By offering both, clients will have a broader range of options in study design. Additionally, Culex allows programmed sampling of blood and other body fluids without human intervention, at any time, or continuously for 24 hours or more. This approach reduces animal usage and helps to provide stronger data.

“One major benefit of automated sampling is reduced stress in the subject,” said Craig Bruntlett, senior vice president of instrumentation. “Stress can create a significant impact on the physiological parameters and can make data difficult to interpret. Reducing stress for the animal can lead to cleaner, more meaningful data.”

Mr. Gien joins the company with 10 years of experience in biomedical research, extensive rodent surgery capability and familiarity with the automated Culex system. “His experience and surgical skills will expand the capability of the BASi PK/PD laboratory in Mt. Vernon, IN,” said director of toxicology, David Hopper.


Click here to learn more about BASi